Abbott Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Core Insights - Abbott Laboratories is set to release its third-quarter earnings results on October 16, with analysts expecting earnings of $1.2 per share, an increase from $1.14 per share in the same period last year [1] - The company is projected to report revenue of $10.55 billion for the quarter [1] - Abbott's board declared a quarterly common dividend of 55 cents per share on September 19 [1] - Abbott shares experienced a decline of 0.6%, closing at $116.05 [1] Analyst Ratings - Raymond James analyst Jayson Bedford maintained an Outperform rating and raised the price target from $122 to $129, with an accuracy rate of 67% [2] - Evercore ISI Group analyst Vijay Kumar also maintained an Outperform rating, increasing the price target from $120 to $124, with an accuracy rate of 60% [2] - Jefferies analyst Raj Denhoy reiterated a Hold rating with a price target of $120, achieving an accuracy rate of 76% [2] - Piper Sandler analyst Adam Maeder initiated coverage with an Overweight rating and a price target of $131, holding an accuracy rate of 60% [2] - Citigroup analyst Joanna Wiensch maintained a Buy rating and raised the price target from $119 to $127, with an accuracy rate of 60% [2]